INTRODUCTION
Psoriatic disease is a common chronic immune-mediated systemic inflammatory disease, most often presenting as chronic plaque psoriasis with erythematous, scaly lesions that cause pain, pruritus, and cosmetic burden.1 The pathophysiology involves immune dysregulation, particularly through the IL-23/IL-17 inflammatory axis, which drives both skin inflammation and broader systemic disease.2
Beside the dermatological symptoms, well-established comorbidities in psoriasis include metabolic disorders such as obesity and metabolic syndrome, cardiovascular complications, and mental disorders such as anxiety and depression.3 They contribute to substantial impairment in health-related quality of life, such as disruption to daily functioning, interpersonal relationships, and psychological well-being.4,5 As a consequence, sleep disturbances are an increasingly recognized aspect of psoriasis-related morbidity.6
Targeted biologic therapies, such as IL-17 and IL-23 inhibitors, have revolutionized treatment approaches for moderate-to-severe psoriasis. These agents achieve skin clearance and can effectively reduce systemic inflammatory burden.7 However, data on how biologic treatments influence sleep quality still remain limited.
Given the established connections between systemic inflammation, cutaneous symptom burden, and sleep disruption, biologic therapies may offer previously unrecognized benefits for sleep-related outcomes in psoriasis. The aim of this study was to evaluate the relationship between psoriasis severity, clinical symptoms such as pruritus and pain, dermatology-related quality of life, and sleep quality over time in patients under treatment with IL-17 and IL-23 inhibitors.
Beside the dermatological symptoms, well-established comorbidities in psoriasis include metabolic disorders such as obesity and metabolic syndrome, cardiovascular complications, and mental disorders such as anxiety and depression.3 They contribute to substantial impairment in health-related quality of life, such as disruption to daily functioning, interpersonal relationships, and psychological well-being.4,5 As a consequence, sleep disturbances are an increasingly recognized aspect of psoriasis-related morbidity.6
Targeted biologic therapies, such as IL-17 and IL-23 inhibitors, have revolutionized treatment approaches for moderate-to-severe psoriasis. These agents achieve skin clearance and can effectively reduce systemic inflammatory burden.7 However, data on how biologic treatments influence sleep quality still remain limited.
Given the established connections between systemic inflammation, cutaneous symptom burden, and sleep disruption, biologic therapies may offer previously unrecognized benefits for sleep-related outcomes in psoriasis. The aim of this study was to evaluate the relationship between psoriasis severity, clinical symptoms such as pruritus and pain, dermatology-related quality of life, and sleep quality over time in patients under treatment with IL-17 and IL-23 inhibitors.
